Moxaclav 0.6 IV Injection

Indications of Moxaclav - IV 600

Moxaclav - IV 600 is used to treat bacterial infections in the following places for a short period of time:
Tonsillitis, sinusitis, and otitis media are examples of upper respiratory tract infections (including ENT). Acute and chronic bronchitis, lobar and bronchopneumonia are examples of lower respiratory tract infections.

Infections of the genito-urinary tract, such as cystitis, urethritis, and pyelonephritis.

Infections affecting the skin and soft tissues.

Infections of the bones and joints, such as osteomyelitis.

Septic abortion, puerperal sepsis, intra-abdominal sepsis, and other infections

Pharmaceutical Name of Moxaclav - IV 600

Square Pharmaceuticals Ltd

Pharmacology of Moxaclav - IV 600

Pharmacodynamic properties: Co-amoxiclav is an antibacterial combination comprising of the anti-microbial Amoxicillin and the (3-lactamase inhibitor Clavulanic Corrosive. Amoxicillin features a wide range of bactericidal movement against numerous Gram-positive & Gram-negative microorganisms but it is helpless to corruption by (3-lactamases and so the range of action does not incorporate microorganisms, which deliver these proteins. Clavulanic corrosive has the capacity to inactivate a wide run of beta-lactamase proteins commonly found in microorganisms safe to penicillins and cephalosporins. In this way Clavulanic corrosive in this planning secures Amoxicillin from corruption by (3-lactamase chemicals and successfully amplifies the anti-microbial range to grasp a wide extend of microorganisms.

Pharmacokinetic properties: The pharmacokinetics of the two components of Co-amoxiclav is closely coordinated. Top serum levels of both happen approximately one hour after verbal organization. Assimilation of Co-amoxiclav is optimized at the begin of a feast. Both clavulanate and Amoxicillin have moo levels of serum official; almost 70% remains free within the serum. Multiplying the dose of Co-amoxiclav around pairs the serum levels accomplished.

Dosage & Administration of Moxaclav - IV 600

Adults and children over 12 years:

Tablet:

The usual adult dose is one 625 mg Tablet every 12 hours or one 375 mg Tablet every 8 hours.

For more severe infections and infections of the respiratory tract, the dose should be one 1 gm Tablet every 12 hours or one 625 mg Tablet every 8 hours.

Suspension:

Children 6-12 years: 2 teaspoonful every 8 hours.

Children 1-6years: 1 teaspoonful every 8 hours.

Children below 1 year: 25 mg/kg/day in divided doses every 8 hours, for example a 7.5 kg child would require 2 ml suspension t.i.d, Treatment should not be extended beyond 14 days without review.

Forte suspension:

The usual recommended daily dosage: 25/3.6 mg/kg/day in mild to moderate infections (upper respiratory tract infections e.g. recurrent tonsilitis, lower respiratory infections, and skin and soft tissue infections)।

For serious infections: 45/6.4 mg/kg/day for the treatment of more serious infections (upper respiratory tract infections, e.g. otitis media and sinusitis, lower respiratory infections e.g. bronchopneumonia, and urinary tract infections).

Children of 2 to 12 years:
Mild to moderate infections:

25/3.6 mg/kg/day (Suspension)

2-6 years (13-21 kg) 2.5 ml suspension b.i.d

7-12years (22-40kg) 5 ml suspension b.i.d

Serious infections:

45/6.4 mg/kg/day (Forte Suspension)

2-6 years (13-21 kg) 5 ml suspension b.i.d

7-12 years (22-40 kg) 10 ml suspension b.i.d

IV Injection

Adults-

Usually, 1.2 gm every 8 hours

Increased in more serious infections to 1.2 gm every 6 hours

For surgical prophylaxis: The usual dose is 1.2 gm at induction, for high risk procedures (eg. colorectal surgery) up to 2-3 gm may be given every 8 hours.

Children-

0 to 3 months: 30 mg/kg every 8 hours. (every 12 hours in the perinatal period and in premature infants.

3 months to 12 years: Usually 30 mg/kg every 8 hours increased in more serious infection to 30 mg/kg every 6 hours.

Interaction of Moxaclav - IV 600

Some patients treated with Coamoxiclav have been reported to have a prolonged bleeding time and prothrombin time. Like other broad-spectrum antibiotics, Coamoxiclav may reduce the effectiveness of oral contraceptives, so patients should be warned. Concomitant use of allopurinol during treatment with amoxicillin increases the possibility of allergic skin reactions. There are no data on the simultaneous use of Coamoxiclav and allopurinol.

Contraindications

History of allergy to penicillin. Attention should be paid to possible cross-sensitivity with other β-lactam antibiotics. cephalosporins. It is also contraindicated in patients with a history of cholestatic jaundice related to Coamoxiclav or penicillin.

Side Effects of Moxaclav - IV 600

Like amoxicillin, side effects are not common and are mainly mild and short-lived. Diarrhea, pseudomembranous colitis, dyspepsia, nausea, vomiting, and candidiasis have been reported. If oral treatment has gastrointestinal side effects, they can be reduced by taking Coamoxiclav before meals. Reports of hepatitis and cholestatic jaundice are rare, but are usually reversible. Sometimes hives and erythema can occur. There are few reports of erythema multiforme, Stevens-Johnson syndrome, and exfoliative dermatitis. Like other β-lactam antibiotics, angioedema and allergic reactions have also been reported.

Pregnancy & Lactation

Animal studies of oral and parenteral administration of Coamoxiclav have not shown teratogenic effects. The drug has been used orally during human pregnancy in a few cases without adverse effects; however, it is not recommended to use Coamoxiclav during pregnancy unless considered essential by the doctor. During lactation, traces of amoxicillin can be detected in breast milk.

Precautions & Warnings

Patients receiving anticoagulant therapy or severe liver dysfunction should use Coamoxiclav with caution. For patients with moderate or severe renal impairment, the dose should be adjusted. During the administration of high doses of Coamoxiclav, an adequate fluid intake and urine output should be maintained to minimize the possibility of crystalluria.

Therapeutic Class

Broad-spectrum penicillins

Storage Conditions

This should be stored below 25°C, protected from light and moisture. Once reconstituted suspension should be kept in the refrigerator (but not frozen) and should be usedby 7 days. Once reconstituted vial must be used within 20 minutes.